Crossmark

Clinical Outcomes and Predictors of Pathological Response in Triple Negative Breast Cancer Patients Receiving Anthracycline/Taxane-Based Neoadjuvant Therapy

Crossref DOI link: https://doi.org/10.1007/s12262-025-04274-3

Published Online: 2025-01-16

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Çiftçi, Mehmet Sabri https://orcid.org/0000-0003-4113-2416
Uçaner, Burak https://orcid.org/0000-0002-5420-3810
Buldanli, Mehmet Zeki https://orcid.org/0000-0002-6491-7630
Hançerlioğullari, Oğuz https://orcid.org/0000-0003-2289-3834
Kaymak, Şahin https://orcid.org/0000-0003-4717-5791
Çelik, Ertuğrul https://orcid.org/0000-0002-9982-192X
License Information

Text and Data Mining valid from 2025-01-16

Version of Record valid from 2025-01-16
More Information

Article History

Received: 19 May 2024

Accepted: 31 December 2024

First Online: 16 January 2025

Declarations

:

: This study was approved by the University of Health Sciences Gülhane Training and Research Hospital Clinical Researches Ethics Committee, Ankara, Turkey (date: 24.11.2022, decision no.: 2022/146).

: The authors declare no competing interests.

Document is current

Any future updates will be listed below